Pipeline
ADEL-Y03
ADEL-Y03
β2-microglobulin antibody
Target Type
MHC-I - free (unbound)
β2-microglobulin (β2m)
Indication
Alzheimer’s Disease, Aging, Fibrosis (Kidney, Liver, Lung), Cancer, Inflammation
Development stage
Preclinical efficacy
Target
MHC-I – free (unbound) β2-microglobulin (β2m)
- Known as systemic pro-aging factor that impairs cognitive function.
- Increased in patient’s body fluid of Alzheimer’s disease (AD), aging, fibrosis, multiple myeloma, etc.
Strategy
ADEL-Y03 selectively recognizes only free beta 2-microglobulin (free-β2m), not the form bound to MHC-1.
Summary
- Reduction of amyloid beta and inflammation and improvement of cognitive dysfunction in Alzheimer’s disease animal model
- Reduction of fibrosis and/or biomarker in kidney and liver fibrosis animal model
Competitive advantages
Eliminate concerns about side effects
Since Y03 is not bind to the MHC-1-β2m complex form, there is no concern about side effects such as decreased immune function.
Expansion of applicable species and indications
β2m has high homology between species and relevance to various diseases, so Y03 is easy to expand application and indication.
Etc.
Hemodialysis filter (medical device)
Development stage
- Obtain a clone
- In vivo safety and efficacy
- Pipelines
- Discovery
- Preclinical
- Clinical
ADEL-Y03
β2m-target